Comments and Letters

  • ACLA Comments on FDA Draft Guidance on LDTs

    February 02, 2015
    ...
  • ACLA Letter to House Energy and Commerce Regarding SGR Hearing

    January 29, 2015
      Dear Chairman Pitts and Ranking Member Green:   The American Clinical Laboratory Association (ACLA) commends you for holding the recent hearing entitled: “A Permanent Solution to the SGR: The Time is Now,” examining many of the critical policy issues involved with the existing Medicare physician reimbursement methodology and potential paths forward, including possible funding offsets.   ACLA is a not-for-profit association representing theContinue Reading »...
  • AARP Letter on Self-Referral

    December 16, 2014
    ...
  • ACLA Written Statement for 21st Century Cures Hearing on LDT Regulation

    September 08, 2014
      Statement Of Alan Mertz, President, The American Clinical Laboratory Association For U.S. House of Representatives Energy and Commerce Committee Subcommittee on Health Hearing on 21st Century Cures: Examining the Regulation of Laboratory-Developed Tests September 9, 2014 9:30 a.m. 2322 Rayburn House Office Building   Introduction Chairman Pitts, Ranking Member Pallone, and members of the Subcommittee, the American Clinical Laboratory Association (ACLA) is pleasedContinue Reading »...
  • ACLA Comments on PFS Proposed Rule for CY 2015

    August 28, 2014
      See the original PDF here.     August 27, 2014 Administrator Marilyn Tavenner Centers for Medicare and Medicaid Services Department of Health and Human Services Room 445-G Hubert H. Humphrey Building 200 Independence Avenue SW Washington, DC 20201 RE: Medicare Program; Revisions to Payment Policies under the Physician Fee Schedule, Clinical Laboratory Fee Schedule, Access to Identifiable Data for the Center for MedicareContinue Reading »...
  • ACLA PAMA Written Statement

    August 04, 2014
    August 4, 2014 Mr. Glenn McGuirk Center for Medicare Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, Maryland 21244 Dear Mr. McGuirk, The American Clinical Laboratory Association (“ACLA”) appreciates the opportunity to submit this written statement on implementation of section 216 of the Protecting Access to Medicare Act of 2014 (“PAMA”), which adds section 1834A to the Social Security Act to reformContinue Reading »...
  • ACLA Response to LDT Demo Notice

    July 02, 2014
    July 1, 2014 Major General Richard W. Thomas, MD Chief Medical Officer and Director Defense Health Agency, Healthcare Operations Directorate 7700 Arlington Boulevard Falls Church, VA 22042 Dear General Thomas: On behalf of the American Clinical Laboratory Association (“ACLA”) and our members, I am writing to express our appreciation for the recent action by the Defense Health Agency (“DHA”) to establish a demonstration projectContinue Reading »...
  • ACLA, AdvaMedDx, and The Coalition for 21st Century Medicine Joint PAMA Implementation Letter to CMS

    June 23, 2014
    June 23, 2014 Ms. Anne E. Tayloe Hauswald, Director Division of Ambulatory Services Center for Medicare Centers for Medicare and Medicaid Services 7500 Security Boulevard Baltimore, Maryland 21244 Dear Ms. Hauswald, Thank you for meeting with us on May 19, 2014 to discuss implementation of Section 216 of the Protecting Access to Medicare Act of 2014 (“PAMA”), which adds Section 1834A to the SocialContinue Reading »...
  • ACLA Senate Letter Supporting S. 2410 – The Carl Levin National Defense Authorization Act

    June 12, 2014
    ...
  • ACLA House Letter Supporting S. 2410 – The Carl Levin National Defense Authorization Act

    June 12, 2014
    ...
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17